34 articles for K Maeda
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Concise SAR Exploration Based on the"Head-to-Tail" Approach: Discovery of PI4KIIIa Inhibitors Bearing Diverse Scaffolds.
Japan Tobacco
Development of novel NK3 receptor antagonists with reduced environmental impact.
Kyoto University
SAR Exploration Guided by LE and Fsp(3): Discovery of a Selective and Orally Efficacious ROR¿ Inhibitor.
Central Pharmaceutical Research Institute
Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptorß agonists.
Sanwa Kagaku Kenkyusho
Identification of novel D-amino acid oxidase inhibitors by in silico screening and their functional characterization in vitro.
Kitasato University
Discovery of orally available spirodiketopiperazine-based CCR5 antagonists.
Minase Research Institute
Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite.
Ono Pharmaceutical
Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.
Ono Pharmaceutical
bis(2-(Acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein.
Research Triangle Institute
Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.
Ono Pharmaceutical
Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.
Central Pharmaceutical Research Institute
Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.
Ono Pharmaceutical
Synthesis and SAR of 2-phenyl-1-sulfonylaminocyclopropane carboxylates as ADAMTS-5 (Aggrecanase-2) inhibitors.
Central Pharmaceutical Research Institute
Spirodiketopiperazine-based CCR5 antagonists: Improvement of their pharmacokinetic profiles.
Minase Research Institute
Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C-induced HIV latency reversal.
Tokyo Medical and Dental University
Design and synthesis of unique morphinan-type molecules: Their application to the search for the unexplored binding domain between opioid receptors and morphinan ligands.
University of Tsukuba
Discovery and SAR of JTE-151: A Novel RORγ Inhibitor for Clinical Development.
Japan Tobacco
Synthesis and evaluation of DAG-lactone derivatives with HIV-1 latency reversing activity.
Tokyo Medical and Dental University (TMDU)
S-(2-(acylamino)phenyl) 2,2-dimethylpropanethioates as CETP inhibitors.
Central Pharmaceutical Research Institute
Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains.
Kyoto University
Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class.
Japan Tobacco
Discovery of Selective Transforming Growth Factor β Type II Receptor Inhibitors as Antifibrosis Agents.
Japan Tobacco
4-Aryl/cycloalkyl-5-phenyloxazole derivatives as selective COX-2 inhibitors.
Central Pharmaceutical Research Institute
Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders.
Japan Tobacco
Discovery of a novel unsymmetrical structural class of HCV NS5A inhibitors with low picomolar antiviral activity.
Japan Tobacco
Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity.
Japan Tobacco
INHIBITORS AND DEGRADERS OF JANUS KINASE 2
H. Lee Moffitt Cancer Center and Research Institute
Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease.
Academia Sinica